Although these inhibitors have recently entered clinical trials for the treatment of various hematological malignancies, the effectiveness of these agents in several cancers is often limited by chemoresistance, which has most commonly been ascribed to high expression levels of other anti-apoptotic BCL-2 family members, particularly MCL-1 [7, 8, 10-15]. The gene discussed is BCL2; the disease is cancer.